Stem Cell Transplant Shows Long-Term Sclerosis Benefit
Adults with systemic sclerosis see promising 10-year survival rates after undergoing an autologous transplant procedure.
Updated on Oct. 30, 2026 in Stroke
Live Poll
Should the medical community prioritize long-term observational studies for rare diseases like systemic sclerosis?
An international study reports that autologous bone marrow transplantation can lead to long-term survival for people with severe systemic sclerosis. Results show a 71% overall survival rate after a decade of follow-up for patients treated between 2012 and 2016.
Why it matters
Systemic sclerosis is a chronic condition that can cause significant disability and organ damage. This research offers insight into the long-term effectiveness of intensive immune system resetting for patients managing the disease's progression.
This observational prospective cohort study followed 80 patients over a median of 9.2 years to assess outcomes. While 60% of participants achieved progression-free survival at 10 years, the findings indicate that 13% experienced estimated non-relapse mortality within that same period.
The players
The Lancet Rheumatology
A peer-reviewed monthly medical journal that focuses on clinical research and health policy related to rheumatic diseases.
EBMT
The European Society for Blood and Marrow Transplantation, a professional organization dedicated to improving the care of patients undergoing stem cell transplants.
The details
The treatment involves autologous hematopoietic cell transplantation, which effectively resets the patient's immune system to reduce the underlying inflammatory processes characteristic of systemic sclerosis. In the study, researchers tracked the modified Rodnan skin score, a standard metric for skin thickening, which dropped from a median of 24 at baseline to 5 after 10 years. Additionally, 43% of the study group remained alive without needing further immunosuppressive medication at the decade mark.
Timeline
Patients underwent their first autologous HCT treatment between 2012 and 2016.
Study results were presented at the EBMT Annual Meeting in 2026.
The full study findings were published in The Lancet Rheumatology in October 2026.
Health Landscape
This research adds to the growing body of evidence surrounding intensive immunomodulatory therapies for severe autoimmune conditions. It updates the long-term data tracking within the European Society for Blood and Marrow Transplantation registry regarding immune system transplantation.
Patients living with severe systemic sclerosis may want to ask their rheumatologist about the current role of autologous stem cell transplantation in their care plan. Because this treatment carries specific risks, including non-relapse mortality, it is essential to discuss whether such intensive interventions align with your individual health profile.
The takeaway
While intensive stem cell transplantation shows potential for long-term control of systemic sclerosis, it remains a significant medical procedure with associated mortality risks. Discussing your disease progression and available treatment spectrum with a specialist is the best way to navigate these clinical options.
Further reading
For broader context on immune system interventions and vascular health, see our latest research in Stroke.
Source note: This article includes information reported by News-Medical.
Live Poll
Should the medical community prioritize long-term observational studies for rare diseases like systemic sclerosis?
